- New firm will leverage 3D Systems’ latest breakthroughs in bioprinting of vascularized human organs and tissues to speed up new drug growth, cut back prices, and in the end cut back or remove the necessity for animal testing
- Unique bioprinted organ-on-a-chip platform, h-VIOS™, created utilizing hydrogels to supply complicated vasculature that helps prolonged life in wholesome or diseased human cells to be used in drug research
- 3D Systems to supply $15 million in seed funding to display efficacy of expertise and business mannequin, with focused revenues of Systemic Bio approaching $100 million yearly inside 5 years
- Taci Pereira named Chief Executive Officer of Systemic Bio, bringing deep experience in bioengineering and bioprinting
ROCK HILL, S.C., Sept. 08, 2022 (GLOBE NEWSWIRE) — Today, 3D Systems (NYSE:DDD) introduced the formation of a brand new, wholly owned firm referred to as Systemic Bio™, a biotech firm targeted on the applying of superior bioprinting applied sciences to pharmaceutical drug discovery and growth. Systemic Bio will leverage 3D Systems’ breakthrough, production-level bioprinting expertise to create extraordinarily exact vascularized organ fashions utilizing biomaterials and human cells. These proprietary organs-on-chips may be manufactured reproducibly in giant portions, after which perfused with any desired drug compound to check drug metabolism and the results on wholesome or diseased tissue on the earliest phases of new pharmaceutical drug growth. The potential to precisely simulate human response to an experimental drug within the laboratory, early within the growth course of, gives the potential to considerably cut back each the excessive prices and prolonged occasions required for pharmaceutical corporations to carry a brand new drug to market. In addition, this strategy might ultimately cut back and even remove the necessity for animal testing as a precursor to full-scale human trials for brand spanking new drug growth.
Systemic Bio’s efforts will likely be supported by an preliminary $15 million seed funding from 3D Systems, which, given the maturity of the underlying supplies and course of expertise, is envisioned to assist them via the start-up part, bridging them to a cloth income degree and profitability. Systemic Bio intends to open an thrilling new progress marketplace for 3D Systems within the pharmaceutical enviornment, making a biotech income stream for the corporate that would strategy $100 million yearly over the following 5 years.
3D Systems is a acknowledged chief within the use of bioprinting to speed up innovation in regenerative medication for each human organ and non-organ functions. In June 2022, United Therapeutics Corporation (NASDAQ:UTHR) introduced that, in partnership with 3D Systems, it had efficiently produced the world’s most complicated 3D-printed object – a human lung scaffold. Systemic Bio will leverage its revolutionary bioprinting options together with 3D Systems’ Print to Perfusion™ course of to bioprint extremely complicated, custom-designed, vascularized tissues for its proprietary organ-on-a-chip platform, referred to as h-VIOS™.
The h-VIOS (human vascularized built-in organ techniques) organ-on-a-chip platform includes plates of cellularized or acellular vascularized three-dimensional scaffolds, and accompanying equipment wanted for drug testing. Unlike different presently obtainable fashions that are created from artificial supplies corresponding to silicone, h-VIOS makes use of hydrogels that rather more carefully resemble human tissues. The mixture of these hydrogels with 3D Systems’ Print to Perfusion course of for cellularization, permits 3D printing of high-resolution scaffolds that very carefully mimic human tissues. A crucial differentiator of this expertise over competing historic tissue engineering approaches is the precision of the printing course of with these distinctive hydrogel supplies. These bioprinted scaffolds may be seeded with human cells from totally different organs, together with each wholesome and diseased, creating tissues to display screen drug candidates for security and efficacy. This human-based, physiologically related platform has the potential to vary the way in which new drug therapies are developed.
Systemic Bio produces these personalized chips on its bioprinters at its facility in Houston, Texas. These bioprinters are succesful of no less than 10x larger construct quantity and as much as 10X increased decision than different obtainable platforms which permits environment friendly, production-grade manufacturing. Systemic Bio is now working to ascertain multi-phase partnerships with pharmaceutical corporations that would result in the invention of promising new medicine. Beyond offering organ-on-a-chip check samples, pharmaceutical corporations might also search to retain Systemic Bio to supply contract analysis providers along with procuring custom-designed h-VIOS to carry out their very own analysis and testing.
To lead the brand new firm, 3D Systems has named Taci Pereira as Systemic Bio’s Chief Executive Officer. Ms. Pereira joined 3D Systems in May 2021 from Allevi, the place she was Chief Scientific Officer. Since that point, she has served as Vice President and General Manager, Bioprinting, main the event and commercialization of analysis instruments for 3D bioprinting functions. She holds a Bachelor of Science in Bioengineering from Harvard University, the place she labored on the Wyss Institute for Biologically Inspired Engineering. Ms. Pereira’s analysis on the Mooney Laboratory for Cell and Tissue Engineering (Wyss) targeted on biomaterials for most cancers immunotherapy, beneath the advisory of David Mooney, Ph.D.
“As the leader of our Allevi business, Taci brought a unique blend of business acumen and bioprinting expertise that has enabled our continued growth in laboratory solutions,” mentioned Menno Ellis, govt vp, healthcare options, 3D Systems. “Her knowledge, passion, and demonstrated leadership position Taci very well for her new role as CEO of Systemic Bio. I’m confident that the solutions her team delivers can have a transformative impact in the field of pharmaceutical drug discovery and contribute meaningfully to the exciting growth we have envisioned for our healthcare business.”
Dr. Jeffrey Graves, president and CEO of 3D Systems added, “I am pleased and inspired by the progress we continue to make in the emerging field of regenerative medicine. The complexity and precision that we have now demonstrated using biocompatible materials and our most advanced production bioprinting platform technology is truly groundbreaking, opening a host of new applications ranging from the laboratory to replacement organs within the human body. In forming Systemic Bio we are applying these core technologies to specifically address critical needs within the pharmaceutical market. With our potential to ultimately manufacture hundreds or even thousands of custom-designed, proprietary human tissue models, pharmaceutical companies can more rapidly and accurately evaluate the efficacy of developmental drugs in the laboratory, with the goal of reducing development time and eventually eliminating the need for animal testing. By leveraging the progress we have made on our core bioprinting technologies, we are now in a unique position to create this new business — bringing added value to our shareholders, our employees, and, most importantly, to those in need of new, advanced drug therapies to extend, or improve the quality of their lives.”
Systemic Bio is presently providing its h-VIOS platform to pick preliminary companions. Companies which can be considering changing into a Systemic Bio accomplice can go to the web site for extra info.
Forward-Looking Statements
Certain statements made on this launch that aren’t statements of historic or present information are forward-looking statements inside the which means of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contain recognized and unknown dangers, uncertainties and different elements that will trigger the precise outcomes, efficiency or achievements of the corporate to be materially totally different from historic outcomes or from any future outcomes or projections expressed or implied by such forward-looking statements. In many circumstances, forward-looking statements may be recognized by phrases corresponding to “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the adverse of these phrases or different comparable terminology. Forward-looking statements are primarily based upon administration’s beliefs, assumptions, and present expectations and will embody feedback as to the corporate’s beliefs and expectations as to future occasions and developments affecting its business and are essentially topic to uncertainties, many of that are exterior the management of the corporate. The elements described beneath the headings “Forward-Looking Statements” and “Risk Factors” within the firm’s periodic filings with the Securities and Exchange Commission, in addition to different elements, might trigger precise outcomes to vary materially from these mirrored or predicted in forward-looking statements. Although administration believes that the expectations mirrored within the forward-looking statements are cheap, forward-looking statements usually are not, and shouldn’t be relied upon as a assure of future efficiency or outcomes, nor will they essentially show to be correct indications of the occasions at which such efficiency or outcomes will likely be achieved. The forward-looking statements included are made solely as of the date of the assertion. 3D Systems undertakes no obligation to replace or revise any forward-looking statements made by administration or on its behalf, whether or not consequently of future developments, subsequent occasions or circumstances or in any other case, besides as required by regulation.
About 3D Systems
More than 35 years in the past, 3D Systems introduced the innovation of 3D printing to the manufacturing trade. Today, because the main additive manufacturing options accomplice, we carry innovation, efficiency, and reliability to each interplay – empowering our prospects to create merchandise and business fashions by no means earlier than potential. Thanks to our distinctive providing of {hardware}, software program, supplies, and providers, every application-specific answer is powered by the experience of our utility engineers who collaborate with prospects to rework how they ship their services and products. 3D Systems’ options tackle a spread of superior functions in healthcare and industrial markets corresponding to medical and dental, aerospace & protection, automotive, and sturdy items. More info on the corporate is obtainable at www.3dsystems.com.
Investor Contact: [email protected]
Media Contact: [email protected]
Photos accompanying this announcement can be found at
https://www.globenewswire.com/NewsRoom/AttachmentNg/61289c73-0c37-429e-9ec0-5e9f5fffc059
https://www.globenewswire.com/NewsRoom/AttachmentNg/2ca965db-aaf0-417e-adb8-ea03a9490944
